Research

*March 2022* Lung cancer is one of the most common malignant cancers worldwide. Specific genes are known to drive cancer growth in advanced non-small-cell lung cancer (NSCLC) and targeted therapies against these genes and their proteins have significantly improved survival. However, resistance to these therapies inevitably occurs and there is…

*April 2022* Introduction: Previously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. Methods: Patients were identified from a prospective database developed by Boehringer Ingelheim and via literature review. Mutations were…

*May 2022* Key Points NSCLCs harboring oncogenic EGFR mutations or ALK rearrangements can be effectively treated with EGFR and ALK TKIs respectively. The third-generation TKI osimertinib and the ALK TKI lorlatinib are currently the most advanced and effective clinically approved agents in their respective NSCLC subsets; both agents are highly…

*May 2022* Dr. Upal Basu Roy from the LUNGevity Foundation conducts discussions with Drs. Christine Lovly and Helena Yu, along with EGFR Resisters co-founders Ivy Elkins and Jill Feldman. Both Lovely and Yu received research awards from the EGFR Resisters and provide updates on their projects in this video. Dr.…

*April 2022* Ravi Salgia, MD, medical oncologist, professor, and chair, Department of Medical Oncology & Therapeutics Research, and Arthur & Rosalie Kaplan chair in Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, explains how treatment with a tyrosine kinase inhibitor (TKI) in patients with non–small cell…

*April 2022* Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing. Read the transcript and/or watch the video here.

*April 2022* Lung cancer remains the leading cause of cancer-related deaths in the U.S. Lung cancer in non-smokers is more common than many people realize. In fact, lung cancer in never-smokers is now considered the 6th most common cause of cancer deaths in the United States. Each year lung cancer…

*April 2022* Note: Current guidelines state that molecular testing should be conducted at the time of initial diagnosis as well as tumor progression on targeted therapies. Meghan J. Mooradian, MD: I think an important question that many clinicians are faced with now is whether to use blood-based assays, tissue-based assays,…